MarketCap
Facebook
X
Telegram
HOOKIPA Pharma Balance Sheet 2024-2011 | HOOK
Brief overview of HOOKIPA Pharma 's assets and capital
The review uses the five latest available annual reports between 2020 and 2024.
Assets fell from $187.8 million to $82.5 million. This may reflect either deliberate optimization or a reduction in business scale.
Funding shifted toward liabilities: they gained -1.1%, compared with -56.1% for assets.
Internal capital represents 62% of the balance sheet, previously 83.1%. This is a strong capital position.
Cash exceeds interest-bearing debt, producing net debt of -$38.8 million. The balance sheet therefore carries a net cash position.
The cash reserve occupies 48.1% of the balance sheet, previously 76.2%. It is one marker of short-term resilience.
Retained earnings are negative at -$412.8 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Balance sheet takeaway
HOOKIPA Pharma has a workable but not unconditionally strong balance sheet. Resilience depends on sustained earnings and liability control.
Annual Balance Sheet HOOKIPA Pharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-38.8 M | -112 M | -109 M | -61.3 M | -137 M | -108 M | -44.2 M | -57.6 M | - | - | - | - | - | - |
Long Term Debt |
323 K | 3.8 M | 2.31 M | 3.91 M | 4.54 M | 3.5 M | 4.39 M | 3.74 M | - | - | - | - | - | - |
Long Term Debt Current |
552 K | 1.64 M | 1.69 M | 1.68 M | 2 M | 1.81 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
6.68 M | 29.5 M | 32.3 M | 8.8 M | 10.6 M | 11.1 M | 9.16 M | 112 M | - | - | - | - | - | - |
Total Current Liabilities |
24.7 M | 42 M | 35.6 M | 27.7 M | 21.1 M | 14.8 M | - | - | - | - | - | - | - | - |
Total Liabilities |
31.3 M | 71.5 M | 67.9 M | 36.5 M | 31.7 M | 25.8 M | 23.9 M | 116 M | - | - | - | - | - | - |
Deferred Revenue |
4.76 M | 14.6 M | 15.7 M | 5.54 M | 4.63 M | 4.32 M | 7.45 M | 725 K | - | - | - | - | - | - |
Retained Earnings |
-413 M | -369 M | -288 M | -223 M | -147 M | -103 M | -60 M | -43.7 M | - | - | - | - | - | - |
Total Assets |
82.5 M | 161 M | 170 M | 126 M | 188 M | 144 M | 68.3 M | 73.7 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
39.7 M | 117 M | 113 M | 66.9 M | 143 M | 113 M | 48.6 M | 61.4 M | - | - | - | - | - | - |
Book Value |
51.2 M | 89.9 M | 103 M | 89.6 M | 156 M | 118 M | 44.4 M | -42.7 M | - | - | - | - | - | - |
Total Shareholders Equity |
51.2 M | 89.9 M | 103 M | 89.6 M | 156 M | 118 M | -60.4 M | -42.7 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet HOOKIPA Pharma
| 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
284 K | 1.62 M | 3.39 M | - | 1.12 M | 1.16 M | 2.3 M | 2.31 M | 2.61 M | 2.79 M | 5.95 M | 3.91 M | 6.21 M | 6.36 M | 300 K | 6.56 M | 300 K | 300 K | 300 K | 7.3 M | 300 K | 300 K | 460 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
10.5 M | 9.36 M | 11.1 M | - | 28.4 M | 32.5 M | 35.4 M | 32.3 M | 12.1 M | 13 M | 16.6 M | 8.8 M | 7.45 M | 6.35 M | 9.77 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 9.16 M | 9.16 M | 9.16 M | 9.16 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
27.2 M | 37.9 M | 39 M | - | 69 M | 78.8 M | 79.6 M | 67.9 M | 38.2 M | 40.3 M | 47.8 M | 36.5 M | 34.1 M | 40.2 M | 29.9 M | 31.7 M | 31.7 M | 31.7 M | 31.7 M | 25.8 M | 25.8 M | 25.8 M | 25.8 M | 23.9 M | 23.9 M | 23.9 M | 23.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
3.63 M | 5.33 M | 4.1 M | - | 16.1 M | 19.7 M | 19 M | 15.7 M | 7.52 M | 9.83 M | 10.7 M | 5.54 M | 2.37 M | 3.02 M | 3.22 M | 3.75 M | 3.75 M | 3.75 M | 3.75 M | 3.59 M | 3.59 M | 3.59 M | 3.59 M | 6.62 M | 6.62 M | 6.62 M | 6.62 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-428 M | -388 M | -374 M | - | -344 M | -325 M | -307 M | -288 M | -275 M | -257 M | -241 M | -223 M | -202 M | -181 M | -164 M | -147 M | -147 M | -147 M | -147 M | -103 M | -103 M | -103 M | -103 M | -60 M | -60 M | -60 M | -60 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
61.3 M | 110 M | 125 M | - | 164 M | 191 M | 163 M | 170 M | 152 M | 172 M | 196 M | 126 M | 142 M | 166 M | 170 M | 188 M | 188 M | 188 M | 188 M | 144 M | 144 M | 144 M | 144 M | 68.3 M | 68.3 M | 68.3 M | 68.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
40.3 M | 59.8 M | 77.2 M | 93 M | 108 M | 136 M | 110 M | 112 M | 101 M | 119 M | 142 M | 65.9 M | 82.7 M | 103 M | 128 M | 143 M | 143 M | 143 M | 143 M | 113 M | 113 M | 113 M | 113 M | 48.6 M | 48.6 M | 48.6 M | 48.6 M | 61.4 M | - | - | - | 13.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
34.1 M | 71.8 M | 86.1 M | - | 95.1 M | 112 M | 83.5 M | 103 M | 113 M | 132 M | 148 M | 89.6 M | 108 M | 126 M | 140 M | 156 M | 156 M | 156 M | 156 M | 118 M | 118 M | 118 M | 118 M | 44.4 M | 44.4 M | 44.4 M | 44.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
34.1 M | 71.8 M | 86.1 M | 105 M | 95.1 M | 112 M | 83.5 M | 103 M | 113 M | 132 M | 148 M | 89.6 M | 108 M | 126 M | 140 M | 156 M | 156 M | 156 M | 156 M | 118 M | 118 M | 118 M | 118 M | -60.4 M | -60.4 M | -60.4 M | -60.4 M | -42.7 M | - | - | - | -32.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of HOOKIPA Pharma , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
